Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 3 | — | — | 3 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 2 | — | — | 2 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | 2 | — | — | 2 |
Peripheral nervous system diseases | D010523 | — | G64 | — | — | 2 | — | — | 2 |
Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | 2 | — | — | 2 |
Drug common name | Ruboxistaurin |
INN | ruboxistaurin |
Description | Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1 |
PDB | — |
CAS-ID | 169939-94-0 |
RxCUI | — |
ChEMBL ID | CHEMBL91829 |
ChEBI ID | — |
PubChem CID | 153999 |
DrugBank | — |
UNII ID | 721809WQCP (ChemIDplus, GSRS) |